Neoadjuvant chemotherapy for ovarian cancer: do we have enough evidence?

Affiliations

Comment

Sokbom Kang. Lancet. 2015.

. 2015 Jul 18;386(9990):223-4.

doi: 10.1016/S0140-6736(14)62259-5. Epub 2015 May 19.

¹ National Cancer Center, Goyang, 411-769, South Korea. Electronic address: sokbom@gmail.com.

No abstract available

Comment on

Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial.
Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, Luesley D, Perren T, Bannoo S, Mascarenhas M, Dobbs S, Essapen S, Twigg J, Herod J, McCluggage G, Parmar M, Swart AM. Kehoe S, et al. Lancet. 2015 Jul 18;386(9990):249-57. doi: 10.1016/S0140-6736(14)62223-6. Epub 2015 May 19. Lancet. 2015. PMID: 26002111 Clinical Trial.